65,437 trials
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Efficacy and Safety of SPN-810 on the Frequency of Impulsive Aggression (IA) Measured by the Impulsive Aggression Diary — -54.12; -51.64 Percent Change of IA behaviors…
Cerebrovascular Stroke · Large-Artery Atherosclerosis (Embolus/Thrombosis) · Intracranial Arteriosclerosis
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 1; 0; 1 Participants
Pain, Postoperative · Hip Pain Chronic
Primary: Numeric Rating Scale (NRS) Pain Score — 4.0; 2.8 units on a scale
Phantom Limb Pain · Neuroma Amputation
Primary: Numeric Rating Scale (NRS) for Pain at 6 Months — 4 Participants
Dental Implants
Primary: Percent of Survived Implants at Time of the Follow-up Visit — 3; 382; 0 Implants
Breast Cancer
Primary: Reporting Receipt of MRI Breast Screening at Any Time — 32.34 percentage of participants
Quadriceps Muscle
Primary: Muscle Function — 11.0; 13.1 rad/s
ADHD · Oppositional Defiant Disorder
Primary: Change in Child Symptom Inventory-4 (CSI-4) Parent Checklist ADHD Combined Type Symptom Severity Score — 0.82 score on a scale
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events in SRD Part — 0.0; 0.0; 0.0; 33.3 Percentage of participants
Anxiety · Depression · Stress Disorders, Post Traumatic
Primary: Change in Utilization of Services (30 Days) — 53; 23; 40 Participants
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs). — 50.0; 16.7; 66.7; 33.3 Percentage of participants
Malignant Melanoma
Primary: Composite Rate of Pyrexia Related Events — 7.6 Percentage of participants
Primary Prevention of Sudden Cardiac Arrest · Secondary Prevention of Sudden Cardiac Arrest
Primary: Number of Participants Free From Type I Complication — 1869 Participants
Bilateral Cataract · Presbyopia
Primary: Binocular Defocus Curve — 0.07; -0.05; -0.08; -0.05 logMAR
Chronic Obstructive Pulmonary Disease (COPD) · COPD
Primary: PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total — 5.4025 h*ngEq/mL